% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AfsharOromieh:265695,
      author       = {A. Afshar-Oromieh and M. Eiber and W. Fendler and M.
                      Schmidt and K. Rahbar and H. Ahmadzadehfar and L. Umutlu and
                      B. Hadaschik and O. W. Hakenberg and P. Fornara and J. Kurth
                      and O. Neels$^*$ and H.-J. Wester and M. Schwaiger and K.
                      Kopka$^*$ and U. Haberkorn and K. Herrmann and B. J. Krause},
      collaboration = {D. G. f. U. e. V. and D. R. e. V.},
      title        = {{P}rocedure {G}uideline for {P}rostate {C}ancer {I}maging
                      with {PSMA}-ligand {PET}/{CT}.[{DGN}-{H}andlungsempfehlung
                      ({S}1-{L}eitlinie) – {PSMA}-{L}iganden-{PET}/{CT} in der
                      {D}iagnostik des {P}rostatakarzinoms – {S}tand: 01/2022
                      – {AWMF}-{R}egisternummer: 031-055].},
      journal      = {Nuklearmedizin},
      volume       = {62},
      number       = {1},
      issn         = {0029-5566},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {DKFZ-2023-00290},
      pages        = {5 - 19},
      year         = {2023},
      abstract     = {PSMA-PET/CT for imaging prostate cancer (PC) has spread
                      worldwide since its clinical introduction in 2011. The
                      majority of experiences have been collected for
                      PSMA-PET-imaging of recurrent PC. Data for primary staging
                      of high-risk PC are highly promising. Meanwhile, a plethora
                      of PSMA-ligands are available for clinical use (e. g.
                      68Ga-PSMA-11, $68Ga-PSMA-I\&T,$ 68Ga-PSMA-617, 18F-DCFBC,
                      18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7 and 18F-JK-PSMA-7).
                      However, an official approval is available only for
                      68Ga-PSMA-11 (approved by the US FDA in 2020) and 18F-DCFPyL
                      (approved by the US FDA in 2021).Recommendations for
                      acquisition times vary from 1-2 h p. i. It has been shown
                      that for the majority of tumour lesions, the contrast in
                      PSMA-PET/CT increases with time. Therefore, additional late
                      imaging can help to clarify unclear findings. PSMA-PET/CT
                      should be performed prior to commencing an androgen
                      deprivation therapy (ADT) since (long term) ADT reduces the
                      visibility of PC lesions. Following injection of
                      PSMA-ligands, hydration and forced diuresis are recommended
                      for PSMA-ligands with primarily excretion via the kidneys in
                      order to increase the visibility of tumour lesions adjacent
                      to the urinary bladder.PSMA-ligands are physiologically
                      taken up in multiple normal organs. For some 18F-labelled
                      PSMA-ligands, presence of unspecific focal bone uptake has
                      been reported. When using these tracers, focal bone uptake
                      without CT-correlate should be interpreted with great
                      caution. Besides prostate cancer, practically all solid
                      tumors express PSMA in their neovasculature thereby taking
                      up PSMA-ligands, although usually at a lower extent compared
                      to PC. Also multiple benign lesions and inflammatory
                      processes (e. g. lymph nodes) take up PSMA-ligands, also
                      usually at lower extent compared to PC.},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36746147},
      doi          = {10.1055/a-1984-8167},
      url          = {https://inrepo02.dkfz.de/record/265695},
}